GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Initiator Pharma A/S INIT.ST · SEK

Health Care · Nasdaq Stockholm · 🇸🇪 Sweden

Compare

2.40

+10.09%

Close of 9 Nov 2026, in SEK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Initiator Pharma A/S

Its shares trade on Nasdaq Stockholm under the ticker INIT.ST. It has been listed since 16 March 2017.

Initiator Pharma A/S is a clinical-stage biotechnology company, which engages in the development of novel therapeutics within the field of mono-amine reuptake transporters targeting central nervous system (CNS)-disorders. The firm focuses on developing drugs for treatment of erectile dysfunction.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
16 Mar 2017

Leadership

Pay as last reported

  • Mikael Søndergaard Thomsen, PhDChief Development Officer, since 2016
  • Annette Colin LövgrenDirector, since 2022
  • Claus Elsborg Olesen, PhDChief Executive Officer & Director, since 2016
  • Torgeir Vaage, PhDChief Financial Officer, since 2016
  • Allan WehnertSenior Vice President-Clinical, R&D Strategy, since 2020
  • Ulf Simonsen, MD, PhDChief Scientific Officer, since 2016
  • Dan Peters, PhDChief Technology Officer, since 2016
  • Gunnar Magnus Modee Persson, MD, PhDChairman, since 2016
  • Claus Elsborg Olesen, PhDChief Executive Officer & Director, since 2016
  • Peter Holm, PhDDirector, since 2016
  • Henrik Kristian MoltkeDirector, since 2016

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Initiator Pharma A/S develops novel therapeutics for CNS disorders in Denmark.
  • The company focuses on mono-amine reuptake transporter targeting in biotechnology.
  • Initiator Pharma A/S is listed on the Copenhagen Stock Exchange since 2017.

Weaknesses

  • The company's business is limited to erectile dysfunction drug development.
  • Initiator Pharma A/S operates in a highly competitive biotechnology sector.
  • No clinical-stage products are currently approved for market use.

Opportunities

  • Expanding into new CNS disorder treatments beyond erectile dysfunction.
  • Collaborating with Danish biotechnology research institutions for innovation.
  • Growing demand for CNS disorder therapeutics in the European market.

Threats

  • Regulatory challenges in the Danish biotechnology regulatory environment.
  • Competition from established pharmaceutical companies in Health Care.
  • Potential delays in clinical trials for CNS disorder treatments.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.